
Insights Into Hepatocellular Carcinoma (HCC) 2023
Perspectives on drivers in treatment decisions in the management of HCC
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center, Phoenix, AZ, USA
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of HCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region